Nurix Therapeutics, Inc. (NRIX)

15.95 -9.87 (-38.23%) USD  |  NASDAQ  |  Nov 04, 16:00
15.99 +0.04 (+0.25%) Pre-Market: 08:54
More

Nurix Therapeutics EPS Diluted (Quarterly) : 4.734 for Aug. 31, 2026

EPS Diluted (Quarterly) Chart

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
August 31, 2026 4.734
May 31, 2026 -0.806
February 28, 2026 -0.792
November 30, 2025 -0.8226
August 31, 2025 -1.027
May 31, 2025 -0.5182
February 28, 2025 -0.6744
November 30, 2024 -0.7467
August 31, 2024 -0.6727
May 31, 2024 -0.7141
February 29, 2024 -0.7562
November 30, 2023 -0.7674
August 31, 2023 -0.6799
May 31, 2023 -0.4474
February 28, 2023 -0.7539
November 30, 2022 -0.866
Date Value
August 31, 2022 -0.8986
May 31, 2022 -1.011
February 28, 2022 -0.9516
November 30, 2021 -0.8462
August 31, 2021 -0.6498
May 31, 2021 -0.6023
February 28, 2021 -0.626
November 30, 2020 -0.5145
August 31, 2020 -1.77
May 31, 2020 0.1959
February 29, 2020 -0.957
November 30, 2019 -0.348
August 31, 2019 -0.2206
May 31, 2019 -0.0793
February 28, 2019 -0.2074

EPS Diluted (Quarterly) Range, Past 5 Years

View EPS Diluted (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Quarterly) Benchmarks

View EPS Diluted (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 1.942
ACADIA Pharmaceuticals, Inc. 0.1822
Alnylam Pharmaceuticals, Inc. 15.72
Anika Therapeutics, Inc. 0.2412
Savara, Inc. -0.1587

EPS Diluted (Quarterly) Related Metrics

Net Income (Quarterly) 549.81M
Revenue (Quarterly) 673.06M
Total Expenses (Quarterly) 123.26M
Enterprise Value 758.82M
Gross Profit Margin (Quarterly) 99.46%
Profit Margin (Quarterly) 81.69%
Earnings Yield 14.50%
Operating Earnings Yield 16.80%
Normalized Earnings Yield 14.50